Skip to main content

Ban Randy's Form 4 filing

Inspire Medical Systems, Inc.INSP · filed Aug 19, 2024

Accession no.
0001104659-24-090984
Filed
Aug 19, 2024
Trade date
Aug 15-16, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 11 non-derivative transactions and 2 derivative transactions. Open-market sales total $4.03M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ban RandyCIK 0001737127Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 15, 2024Common StockMOption exerciseAcquired+16,139$42.15+$680,258.8519,195Direct
Aug 15, 2024Common StockSSaleDisposed−776$189.06F2−$146,710.5618,419Direct
Aug 15, 2024Common StockSSaleDisposed−1,659$190.20F3−$315,541.816,760Direct
Aug 15, 2024Common StockSSaleDisposed−2,072$191.92F4−$397,658.2414,688Direct
Aug 15, 2024Common StockSSaleDisposed−1,150$192.60F5−$221,49013,538Direct
Aug 15, 2024Common StockSSaleDisposed−8,132$193.92F6−$1,576,957.445,406Direct
Aug 15, 2024Common StockSSaleDisposed−2,350$194.91F7−$458,038.53,056Direct
Aug 16, 2024Common StockMOption exerciseAcquired+4,861$42.15+$204,891.157,917Direct
Aug 16, 2024Common StockSSaleDisposed−900$187.10F8−$168,3907,017Direct
Aug 16, 2024Common StockSSaleDisposed−3,066$188.66F9−$578,431.563,951Direct
Aug 16, 2024Common StockSSaleDisposed−895$189.64F10−$169,727.83,056Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 15, 2024Common StockMOption exerciseDisposed−16,139$0.00$04,861Direct
Aug 16, 2024Common StockMOption exerciseDisposed−4,861$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.995 to $189.285. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.08 to $190.845. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.225 to $192.18. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.26 to $193.22. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.4 to $194.32. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.81 to $195.15. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.90 to $187.71. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.255 to $189.24. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote .

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.26 to $189.855. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read the full filing on SEC EDGAR (opens in a new tab)